CatalystMarker
← board

ACLX

distress 0/10 · well-funded / low risk
$115.070%today0% from 52w high
Revenue
$22M
Liquidity
$520M
Runway
2.5 yrs
Shares 1y
—

Price & events

+67.7% over 6M
$64.11$89.60$115Jan 26Apr 26Jul 2614.7Mrating: Guggenheim: Buy → Neutral (2026-02-26)rating: Leerink Partners: Outperform → Market Perform (2026-02-24)rating: Citigroup: Buy → Neutral (2026-02-24)rating: Truist Securities: Buy → Hold (2026-02-24)rating: UBS: Buy → Neutral (2026-02-24)rating: Evercore ISI Group: Outperform → In-Line (2026-02-24)rating: Stifel: Buy → Hold (2026-02-24)rating: HC Wainwright & Co.: Buy → Neutral (2026-02-23)
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.1%
1W
+0.4%
1M
+68.6%
3M
+33.8%
6M
+77.8%
1Y
—
2Y
—
5Y
+46.1%
All

Overview

Volume
0
52 Week Range
$52.80 – $115
Float Shares
42.96M
Short %
4.18%
% Held by Insiders
11.67%
% Held by Institutions
90.33%
Beta
0.25

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 0

  • No catalyst news yet.

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: — · 0 offerings/1y · 0 PIPEs
  • none
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

hold · target $112 (-2% upside) · 10 analysts
  • 2026-02-26GuggenheimBuy → Neutral
  • 2026-02-24Leerink PartnersOutperform → Market Perform
  • 2026-02-24CitigroupBuy → Neutral
  • 2026-02-24Truist SecuritiesBuy → Hold
  • 2026-02-24UBSBuy → Neutral
  • 2026-02-24Evercore ISI GroupOutperform → In-Line

Competitors

  • none identified

Recent news

  • none

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.